Spark Therapeutics, Inc. (ONCE) Stock Moves Down and Here’s Why

Spark Therapeutics, Inc. (NASDAQ: ONCE) shares fell in early trading yesterday lower trade volume than normal after a number of analysts weighed in on the investing value of the stock with a downgraded rating.

U.S. stocks flipped between small losses and gains early Tuesday morning as investors maintained a cautious stance following a sharp postelection rally.

The S&P 500 index SPX, -0.04% was off by about 1 point, or less than 0.1%, at 2,267, with seven of the 11 main sectors trading lower. The Dow Jones Industrial Average DJIA, -0.13% was off 33 points, or 0.2%, to 19,853.

Meanwhile, the Nasdaq Composite Index COMP, +0.05% traded in record territory, after closing at an all-time high for the second session in a row on Monday.

Analysts at Vetr Inc. downgraded shares of Spark Therapeutics, Inc. (NASDAQ: ONCE) from Buy to Hold in a research note to investors today. With a rating of Hold on the shares, the company has a 52-week high of $65.99. As a means of comparison, a number of other analysts have commented on the company in recent days, and the company has earned a consensus one-year price target of $61.79, a decrease compared to the opening price of $62.78, a difference of 10.06 percent. Important and integral changes in the company’s procedures, future outlook or industry can cause downgrades as the analysts believe that the future prospects for the security have weakened from the original recommendation.

Yesterday Spark Therapeutics, Inc. (NASDAQ: ONCE) shares last traded at $61.44, which is a drop of $1.05 compared to the previous closing price. Opening at $62.78, they ranged from $61.19 and $63.05 throughout the day.

Spark Therapeutics, Inc. (NASDAQ: ONCE) currently has a market cap of 1.89B.

Spark Therapeutics, Inc. (NASDAQ: ONCE) Average Daily Trading Volume

25,386 shares traded hands yesterday, 48 percent below the norm, out of a total float 30,308,000. lower than normal. Look for trading volume to pick up in the coming days as momentum traders often use increases in trading volume to identify heavy volume accumulation or distribution by institutional investors.

While increased trading for short periods will not mean much will not mean much, however, a trend of heavy trading volume on the buy side over a period of days or weeks sends a positive signal to market traders that institutions may be moving in, so institutional sponsorship is very important.

Institutional sponsorship just refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Institutional investors such as these have teams of analysts researching thousands of stocks. So watching their interests is a good way to ensure you are buying the right stocks.

Spark Therapeutics, Inc. (NASDAQ: ONCE) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By identifying trends, moving averages allow investors to make those trends work in their favor and increase the number of winning trades.

With that in mind, Spark Therapeutics, Inc. (NASDAQ: ONCE) now has a 50-day MA of $53.39 and 200-day MA of $55.20. It has traded in a 52-week range between $21.20 – 65.99 and today’s last price is 6.89%% lower than the 52 week high of $65.99.

Earnings growth is a critical factor to consider when investing in stocks and investors watch for companies that have increased their earnings at least 25% or more for the past 3 years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *